Table of Contents
Chapter 1. Global Neuroblastoma Drugs Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer's Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates
Chapter 2. Executive Summary
2.1. Global Neuroblastoma Drugs Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Type
2.3.2. By Route of Administration
2.3.3. By Distribution Channel
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Global Neuroblastoma Drugs Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Global Neuroblastoma Drugs Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Neuroblastoma Drugs Market Size & Forecasts by Type 2022-2032
5.1. Chemotherapy
5.2. Immunotherapy
5.3. Others
Chapter 6. Global Neuroblastoma Drugs Market Size & Forecasts by Route of Administration 2022-2032
6.1. Oral
6.2. Injectable
Chapter 7. Global Neuroblastoma Drugs Market Size & Forecasts by Distribution Channel 2022-2032
7.1. Online
7.2. Offline
Chapter 8. Global Neuroblastoma Drugs Market Size & Forecasts by Region 2022-2032
8.1. North America Neuroblastoma Drugs Market
8.1.1. U.S. Neuroblastoma Drugs Market
8.1.1.1. Type breakdown size & forecasts, 2022-2032
8.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.1.2. Canada Neuroblastoma Drugs Market
8.2. Europe Neuroblastoma Drugs Market
8.2.1. U.K. Neuroblastoma Drugs Market
8.2.2. Germany Neuroblastoma Drugs Market
8.2.3. France Neuroblastoma Drugs Market
8.2.4. Spain Neuroblastoma Drugs Market
8.2.5. Italy Neuroblastoma Drugs Market
8.2.6. Rest of Europe Neuroblastoma Drugs Market
8.3. Asia-Pacific Neuroblastoma Drugs Market
8.3.1. China Neuroblastoma Drugs Market
8.3.2. India Neuroblastoma Drugs Market
8.3.3. Japan Neuroblastoma Drugs Market
8.3.4. Australia Neuroblastoma Drugs Market
8.3.5. South Korea Neuroblastoma Drugs Market
8.3.6. Rest of Asia Pacific Neuroblastoma Drugs Market
8.4. Latin America Neuroblastoma Drugs Market
8.4.1. Brazil Neuroblastoma Drugs Market
8.4.2. Mexico Neuroblastoma Drugs Market
8.4.3. Rest of Latin America Neuroblastoma Drugs Market
8.5. Middle East & Africa Neuroblastoma Drugs Market
8.5.1. Saudi Arabia Neuroblastoma Drugs Market
8.5.2. South Africa Neuroblastoma Drugs Market
8.5.3. Rest of Middle East & Africa Neuroblastoma Drugs Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Recordati Group
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Eli Lilly and Company
9.3.3. Bristol-Myers Squibb Company
9.3.4. Y-mabs Therapeutics, Inc.
9.3.5. MacroGenics Inc.
9.3.6. AstraZeneca plc
9.3.7. United Therapeutics Corporation
9.3.8. Pfizer Inc.
9.3.9. Teva Pharmaceutical Industries Ltd.
9.3.10. Cellectar Biosciences, Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes